Eribulin

Phase 2Active
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Angiosarcoma

Conditions

Angiosarcoma, Epithelioid Hemangioendothelioma

Trial Timeline

Jan 18, 2018 → Feb 1, 2026

About Eribulin

Eribulin is a phase 2 stage product being developed by Eisai for Angiosarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT03331250. Target conditions include Angiosarcoma, Epithelioid Hemangioendothelioma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (6)

NCT IDPhaseStatus
NCT03840772Phase 2Completed
NCT03637868Phase 2Withdrawn
NCT03331250Phase 2Active
NCT03027245Pre-clinicalCompleted
NCT01669252Phase 2Completed
NCT00908908Phase 1Completed

Competing Products

6 competing products in Angiosarcoma

See all competitors
ProductCompanyStageHype Score
Avelumab + PaclitaxelMerckPhase 2
52
Pembrolizumab plus LenvatinibMerckPhase 2
52
Pazopanib + PaclitaxelNovartisPhase 2
52
regorafenibBayerPhase 2
49
Vusolimogene Oderparepvec (VO) + PembrolizumabReplimunePhase 2
44
AGEN2034 + AGEN1884AgenusPhase 2
44